Interestingly, in vitro evidence has revealed that SARS‐CoV‐2 is more sensitive to IFN‐β‐1 treatment than MERS‐CoV and SARS‐CoV and thus supports the tenet that treatment with IFN‐β‐1 may be beneficial for COVID‐19 patients (Lokugamage, Schindewolf, & Menachery, 2020; Sheahan et al., 2020; Thiel & Weber, 2008). This evidence concerns the gene IFNB1 and COVID-19.